Atrial involvement in arrhythmogenic right ventricular cardiomyopathy patients referred for ventricular arrhythmias ablation

• Published in: Journal of cardiovascular electrophysiology Vol. 29; no. 10; pp. 1388 - 1395
• Main Authors: Wu, Lingmin, Bao, Jingru, Liang, Erpeng, Fan, Siyang, Zheng, Lihui, Du, Zhongpeng, Chen, Gang, Ding, Ligang, Zhang, Shu, Yao, Yan
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.10.2018
• Subjects: Ablation; Arrhythmia; arrhythmogenic right ventricular cardiomyopathy; atrial fibrillation; atrial flutter; Atrium; Cardiomyopathy; Dilation; genotype; Genotype & phenotype; Genotypes; Heart transplantation; Multivariate analysis; Mutation; Myocardium; Regurgitation; Transplantation; Ventricle; arrhythmogenic right ventricular cardiomyopathy; atrial fibrillation; atrial flutter; genotype
• ISSN: 1045-3873; 1540-8167
• DOI: 10.1111/jce.13666

Background Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable myocardium disorder that predominantly affects the ventricle. Little is known about atrial involvement. This study aimed to assess atrial involvement, especially the role of genotype on atrium in ARVC. Methods The incidence, characterization and predictors of atrial involvement were investigated. Nine known ARVC‐causing genes were screened and the correlation between genotype and atrial involvement was assessed. Results Right atrium (RA) dilation, left atrium (LA) dilation, and sustained atrial tachyarrhythmias (ATa) were found in 45, 16 and 3 patients, respectively. Gene mutations were identified in 64 (64.0%) patients. Mutation carriers showed more RA dilation than noncarriers (54.7% vs. 27.8%, P = 0.009), and no difference in LA dilation and ATa. Multivariate analysis showed tricuspid regurgitation (OR: 18.867; 95% CI: 1.466‐250.000; P = 0.024) increased the risk of RA dilation and decreased left ventricular ejection fraction (LVEF) (OR: 1.134; 95% CI: 1.002‐1.272; P = 0.031) correlated with LA dilation, whereas genotype showed no significant effect. At a median follow‐up time of 91 months, 7 patients died and 1 patient accepted heart transplantation. New‐onset RA dilation, LA dilation, and sustained ATa were found in 8, 7, and 6 patients, respectively. Atrial involvement was not associated with the long‐term survival. Despite mutation carriers showing more RA dilation, Kaplan‐Meier analysis showed genotype was not associated with atrial involvement. Conclusion Atrial involvement was common in ARVC. Tricuspid regurgitation and decreased LVEF increased the risk for atrial dilation. Genotype was not associated with atrial involvement.